Katy A. Lloyd
-
- T-cell and B-cell Immunology 3
- Immunotherapy and Immune Responses 3
- Galectins and Cancer Biology 3
- Immune Cell Function and Interaction 2
-
- Monoclonal and Polyclonal Antibodies Research 9
-
- CAR-T cell therapy research 4
-
- Glycosylation and Glycoproteins Research 2
- vaccines and immunoinformatics approaches 1
- Co-authors
- Sjoerd H. van der BurgJanine SchuurmanCaroline GrönwallThorbald van HallMarjolein SluijterVitalijs OvcinnikovsJim MiddelburgKarin Lundberg
- Journals
- Journal of Biological Chemistry (1 paper)Nature Communications (1 paper)Cancer Cell (1 paper)
- Partner nations
- United StatesNetherlandsUnited Kingdom
In The Last Decade
Katy A. Lloyd
11 papers receiving 262 citations
Hit Papers
Peers
Comparison fields: 5 of 54
- Immunology 178
- Radiology, Nuclear Medicine and Imaging 92
- Rheumatology 46
- Oncology 71
- Immunology and Allergy 10
Countries citing papers authored by Katy A. Lloyd
This map shows the geographic impact of Katy A. Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katy A. Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katy A. Lloyd more than expected).
Fields of papers citing papers by Katy A. Lloyd
This network shows the impact of papers produced by Katy A. Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katy A. Lloyd. The network helps show where Katy A. Lloyd may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Katy A. Lloyd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 17 | |
| 4 | Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacybreakdown → | 2024 | 72 |
| 5 | 2019 | 50 | |
| 6 | 2018 | 34 | |
| 7 | 2017 | 16 | |
| 8 | 2017 | 1 | |
| 9 | 2016 | 7 | |
| 10 | 2015 | 29 | |
| 11 | 2012 | 37 |
About Katy A. Lloyd
Katy A. Lloyd is a scholar working on Immunology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 11 papers that have together received 266 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (9 papers), CAR-T cell therapy research (4 papers), T-cell and B-cell Immunology (3 papers), Immunotherapy and Immune Responses (3 papers), Galectins and Cancer Biology (3 papers), Glycosylation and Glycoproteins Research (2 papers), Immune Cell Function and Interaction (2 papers) and vaccines and immunoinformatics approaches (1 paper). The work is most often cited by research in Immunology (178 citations), Radiology, Nuclear Medicine and Imaging (92 citations) and Rheumatology (46 citations). Katy A. Lloyd has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Sjoerd H. van der Burg, Janine Schuurman, Caroline Grönwall, Thorbald van Hall, Marjolein Sluijter, Vitalijs Ovcinnikovs, Jim Middelburg, Karin Lundberg, Lars Klareskog and Noel F.C.C. de Miranda. Their work appears in journals such as Journal of Biological Chemistry, Nature Communications and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.